Lovenox Generics: FDA’s Split Opinion On ANDA Approval Fully Supported By Court
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision will give FDA ammunition for future battles over biosimilar approvals as Sanofi’s suit against the agency is tossed out. The court notes there was a split within FDA over its five-pronged test for active ingredient sameness, which the judge sees as evidence that the issues were carefully weighed.
You may also be interested in...
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
FDA Heparin Immunogenicity Guidance Addresses ANDA Approvals, Brand Changes
Guidance formalizes five criteria FDA used in making a “sameness” determination for Momenta/Sandoz’s enoxaparin ANDA and lays out an approach to assessing the effect of post-approval NDA changes on a product’s immunogenicity without the need for clinical trials.